Catalyst
Slingshot members are tracking this event:
Interim Phase 1b/2 Results for Merck's (MRK) Keytruda and Eisai's (ESALY) Halaven in Triple-Negative Breast Cancer (TNBC) Presented at the San Antonio Breast Cancer Symposium
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1b/2, Interim Results, Keytruda, Halaven, Metastatic Triple-negative Breast Cancer, Tnbc, San Antonio Breast Cancer Symposium
